Saved Articles
My Lists
My Page
My Content
Log In
360° Search
Network
Hot Spots
Trends
Time Series
Advanced Search Options >>
Give Feedback
Home
Global Issues
Technology
Science
Business
Energy
Countries
Ebixa
Type:
Product
Name:
Ebixa
First reported Feb 04 2013 - Updated Feb 04 2013 -
1 reports
Human medicines European Public Assessment Report (EPAR): Ebixa, memantine, Revision: 21, Authorised
[Published Pending EC decisions and European Public Assess ... - Feb 04 2013]
Entities:
Ebixa
Quotes
According to Professor Nordstrom,
"
If you translate these reductions in risk into absolute figures, it means that for every 100,000 people with Alzheimer's disease, there would be 180 fewer heart attacks — 295 as opposed to 475 every year among those taking ChEIs compared to those not using them.
"
Killing Two Ills with One Pill [Published Daily Rx - Jun 05 2013]
Prof Nordström said:
"
As far as we know, this is the first time that the use of ChEIs has been linked to a reduced risk of heart attacks and deaths from cardiovascular disease in general or from any cause. As this is an observational study, we cannot say that ChEI use is causing the reduction in risk, only that it is associated with a reduction. However, the strengths of the associations make them very interesting from the clinical point of view, although no clinical recommendations should be made on the basis of the results from our study. It would be of great value if a meta-analysis of previous, randomised controlled trials could be performed, as this might produce answers on which clinical recommendations could be based.
"
Alzheimer's disease drugs linked to reduced risk of heart attacks [Published Medical Xpress - Jun 05 2013]
More Content
All (5)
|
News (2)
|
Reports (0)
|
Blogs (1)
|
Audio/Video (0)
|
Fact Sheets (2)
|
Press Releases (0)
sort by:
Date
|
Relevance
Killing Two Ills with One Pill
[Published Daily Rx - Jun 05 2013]
Alzheimer's disease drugs linked to reduced ris...
[Published Medical Xpress - Jun 05 2013]
Human medicines European Public Assessment Repo...
[Published Pending EC decisions and European Public Assess ... - Feb 04 2013]
Fact Sheet for H. Lundbeck A/S
[Published Able2Act - Mar 30 2009]
Fact Sheet for H. Lundbeck A/S
[Published Able2Act - Jul 24 2008]
1
In Focus
Peter Nordström
,
Anders Wimo
,
Bengt Winblad
H Lundbeck AS
,
Exelon Corporation
Umeå University
,
Karolinska Institutet
,
Sveriges Kommuner och Landsting
Alzheimer's Disease
,
Heart Attack
,
Insomnia
,
[more]
Parkinson's Disease
Patient
Central Nervous System
Memantine
Dementia
Myocardial Infarction
Alcohol
Drugs
Vagus Nerve
Anxiety
Mergers & Acquisitions
treatments
Serdolect
,
Circadin
,
Cipralex
,
[more]
Azilect
Lexapro
donepezil
REMINYL
Aricept
Copenhagen
,
Umeå
Denmark
,
Italy
,
United Kingdom
,
[more]
Sweden
United States
Diseases
,
Medication
,
Medicine
,
[more]
Neuroscience
Health
Pending EC decisions and European Public Assess...
,
Able2Act
,
Daily Rx
,
[more]
Medical Xpress
Content Volume
Network
Blogs
sort by:
Date
|
Relevance
Human medicines European Public Assessment Repo...
[Published Pending EC decisions and European Public Assess ... - Feb 04 2013]
1
About
Silobreaker
Press Room
Products
Online Service
On-Premises Software
Contact Us
Sales
Support
Legal
Terms of Use
Privacy Policy
Some image thumbnails are sourced from
Freebase
, licensed under
CC-BY
Copyright (C) 2013 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.